Journal
TRENDS IN IMMUNOLOGY
Volume 26, Issue 11, Pages 565-571Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2005.08.014
Keywords
-
Categories
Ask authors/readers for more resources
Experimental autoimmune encephalomyelitis (EAE) is a useful model for aiding the development of new treatments for MS. All therapies approved for MS ameliorate EAE. Two approved medications, glatiramer acetate and Natalizumab, were developed directly from studies in EAE. Several trials are ongoing in MS after success in EAE, including altered peptide ligands of myelin, DNA vaccines and statins. However, EAE has failed to predict the outcome of certain approaches. The reasons underlying such failures are discussed here.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available